Pharmacoeconomic Value Of Addiction Treatments, Including VIVITROL(R), Published In Leading Healthcare Policy Journal

Tuesday, Sep. 13th 2011 6:40 AM

Alkermes, Inc. (NASDAQ: ALKS) today announced the publication of two new studies in the June issue of The American Journal of Managed Care1,2 evaluating pharmacoeconomic data on addiction treatments, including VIVITROL® (naltrexone for extended-release injectable suspension), with the endpoint of total healthcare costs.

VN:F [1.9.22_1171]
Rating: 0.0/5 (0 votes cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)
Posted on Tuesday, Sep. 13th 2011 6:40 AM | by Share of Cost | in Share of Cost | No Comments »

Leave a Reply

You must be logged in to post a comment.